ZBIO vs JNJ

For growth investors, Zenas BioPharma, Inc.

(ZBIO) is the stronger pick with 100. 0% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Johnson & Johnson (JNJ) offers the better valuation at 41. 2x trailing P/E (20. 6x forward), making it the more compelling value choice. Analysts rate Zenas BioPharma, Inc. (ZBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +59.

0%, compared to -1. 2% for Zenas BioPharma, Inc. (ZBIO). Over 10 years, the gap is even starker: JNJ returned +140. 2% versus ZBIO's -1. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

03β versus Zenas BioPharma, Inc. 's 1. 39β — meaning ZBIO is approximately 4745% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Zenas BioPharma, Inc. (ZBIO) carries a lower debt/equity ratio of 33% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zenas BioPharma, Inc.

(ZBIO) is pulling ahead at 100. 0% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Johnson & Johnson grew EPS -57. 8% year-over-year, compared to -124. 5% for Zenas BioPharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -37. 8% for Zenas BioPharma, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -21. 1% for ZBIO. At the gross margin level — before operating expenses — ZBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ZBIO: 97.

1% to $35. 00.

In this comparison, JNJ (2.

0% yield) pays a dividend. ZBIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

03), 2. 0% yield, +140. 2% 10Y return). Both have compounded well over 10 years (JNJ: +140. 2%, ZBIO: -1. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZBIO is a small-cap high-growth stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while ZBIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.